Eedarapalli Padma, Biswas Nibedan, Coleman Matthew
Department of Obstetrics and Gynaecology, Poole Hospital, NHS Trust, Longfleet Road, Poole BH 15 2JB, UK.
J Reprod Med. 2007 Aug;52(8):730-2.
The rarity of breast cancer in pregnancy and conflict between the optimal maternal therapy and fetal risks make its management challenging. Chemotherapy is the standard treatment for advanced cases. Epirubicin as a combination agent has been reported for breast and other cancers in pregnancy but not as a single agent. We report a case of advanced breast cancer treated with epirubicin neoadjuvant chemotherapy in pregnancy.
A 30-year-old primigravida with multifocal, grade 3 invasive ductal carcinoma, stage T2 N1M0, received 4 cycles of primary epirubicin chemotherapy in pregnancy from 23 weeks' gestation. The chemotherapy was well tolerated by the mother and fetus, and a good response was achieved prior to postnatal combination chemotherapy and definitive surgery.
Epirubicin chemotherapy appears safe and effective in pregnancy.
妊娠期间乳腺癌罕见，且最佳的母体治疗与胎儿风险之间存在冲突，这使得其管理具有挑战性。化疗是晚期病例的标准治疗方法。表柔比星作为联合用药已被报道用于治疗妊娠期间的乳腺癌及其他癌症，但尚未有作为单一药物使用的报道。我们报告一例在妊娠期间接受表柔比星新辅助化疗治疗的晚期乳腺癌病例。
一名30岁初产妇，患有多灶性3级浸润性导管癌，T2 N1M0期，在妊娠23周时接受了4个周期的表柔比星原发性化疗。母亲和胎儿对化疗耐受性良好，在产后联合化疗和确定性手术前取得了良好疗效。
表柔比星化疗在妊娠期间似乎是安全有效的。
